TScan Therapeutics, Inc.TCRXNASDAQ
Loading
Price to Sales: Discounted ValuationCompressed
Percentile Rank50
3Y CAGR+65.9%
5Y CAGR-44.6%
Year-over-Year Change
Price-to-sales ratio
3Y CAGR
+65.9%/yr
Annual compound
5Y CAGR
-44.6%/yr
Recent acceleration
Percentile
P50
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 yr
Consecutive declineCompressed
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 12.58 | -89.6% |
| 2024 | 120.90 | +565.4% |
| 2023 | 18.17 | +559.8% |
| 2022 | 2.75 | -74.0% |
| 2021 | 10.61 | -95.6% |
| 2020 | 241.34 | - |
| 2019 | 0.00 | - |